Showing 4421-4430 of 5910 results for "".
- Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Diseasehttps://modernod.com/news/tarsus-initiates-phase-2a-ersa-trial-evaluating-tp-03-for-the-treatment-of-meibomian-gland-disease/2481015/Tarsus Pharmaceuticals announced that it has enrolled the first patient in a phase 2a clinical trial studying TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of meibomian gland disease (MGD) in patients with Demodex mites. Demodex
- FDA Approves First Biosimilar Interchangeable to Lucentishttps://modernod.com/news/fda-approves-fyb201cimerli-the-first-and-only-biosimilar-to-lucentis/2481012/Coherus BioSciences announced that the FDA has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), d
- Pixium Vision Announces Regulatory Approval of Remote Rehabilitation System for Patients in Clinical Trialshttps://modernod.com/news/pixium-vision-announces-regulatory-approval-of-remote-rehabilitation-system-for-patients-in-clinical-trials/2481010/Pixium Vision announced the approval of the remote rehabilitation system for patients enrolled in the PRIMAvera pivotal trial and the French Feasibility Study in atrophic dry age-related macular degeneration (AMD). The approval was granted by the Ethics Commitee and the Regulatory Autho
- LumiThera Purchases MacuLogix Assetshttps://modernod.com/news/lumithera-purchases-maculogix-assets/2481007/LumiThera announced the purchase of the assets of MacuLogix. Terms of the deal were not disclosed. MacuLogix is the developer of the wearable AdaptDX Pro dark adaptometer, which allows eye care professionals to measure dark adaptation—designed to dia
- Aerie Pharmaceuticals Announces First Patient Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-comet-3-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2481006/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-3” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-3 is the second of three trials in the p
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-davio-2-clinical-trial-of-eyp-1901-for-the-maintenance-treatment-of-wet-amd/2481005/EyePoint Pharmaceuticals, Inc., announced that the first patient has been dosed in the Phase 2 Durasert® and Vorolanib in Ophthalmology 2 (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery antivascular endothelial growth factor (anti-VEGF) treatment for wet
- EyeCare Partners Expands Presence in Virginia with Two Acquisitionshttps://modernod.com/news/eyecare-partners-expands-presence-in-virginia-with-two-acquisitions/2480998/EyeCare Partners (ECP) announced it has entered into an agreement to partner with Commonwealth Eye Care Associates (CECA) and Retina Institute of Virginia (RIV). Financial terms of the deals were not disclosed. Through the partnership with Commonwealth Eye Care Associates, ECP
- Yuyu Pharma Announces First Patient Enrolled in Phase 2 Study of YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-first-patient-enrolled-in-phase-2-clinical-study-evaluating-yp-p10-ophthalmic-solution-for-the-treatment-of-dry-eye-disease/2480996/Yuyu Pharma announced the enrollment of the first patient in a phase 2 clinical study evaluating YP-P10, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties being investigated to treat patients with dry eye disease (DED). Yuyu received cl
- Pixium Vision Announces Successful Implantation of First Patient in the Netherlands in Prima System European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-announces-successful-implantation-of-first-patient-in-the-netherlands-in-prima-system-european-pivotal-trial-primavera/2480993/Pixium Vision announced the successful implantation of the first patient in the Netherlands in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD). This follows approval of the PRIMAvera study by the Dutch Ministry of Health, Welfare and Sport and the open
- RD Fund Announces New Chair and Expansion of Board of Directorshttps://modernod.com/news/rd-fund-announces-new-chair-and-expansion-of-board-of-directors/2480990/The RD Fund (Retinal Degeneration Fund)—the venture arm of the Foundation Fighting Blindness aimed at driving research toward preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases—announced the appointment of Adrienne Graves, P